ESTRO 2020 Abstract Book

S659 ESTRO 2020

to development of brain metastases, time from the first metastases to WBRT, the presence of leptomeningeal, liver and lung metastases were not significant on univariate analysis. Conclusion WBRT is effective in a selected group of patients: 38% of the patients surviving 2 months reported benefit from the treatment resulting in a significant increased survival for this group. However, 27% of the patients died within 2 months. Prognostic factors for an increased survival were low dose dexamethasone use (0-7mg) prior to WBRT and additional treatment options after WBRT. PO-1252 Early palliative care in advanced-stage cancer patients: A retrospective cross-sectional study N. Thakur 1 1 Post Graduate Institute of Medical Education and Research, Radiotherapy and Oncology, Chandigarh, India Purpose or Objective While treating patients with the advanced disease it becomes very challenging for the clinicians to decide as to when the active treatment is justified and when should palliative care be introduced in patient's treatment. American Society of Clinical Oncology (ASCO) suggested that patients with advanced cancer, regardless of patient or outpatient, should receive dedicated palliative care services, early in the disease course, simultaneous with active treatment. Similar recommendations have been proposed by the European Society of Medical Oncology (ESMO). Keeping in view this background, we aimed to study the impact of the introduction of early palliative care into routine oncological management on patient's survival. Material and Methods This retrospective cross-sectional study is based on hospital data for patients who died in the hospice between the year 2017 and 2018. The complete information including age, gender, date of death, diagnosis, procedures, and medical interventions, as well as the date of documentation, was obtained of each patient. Results A total of 27 patients were enrolled in this study. The mean age at presentation was 50.3 years. 11 (40.7%) patients received oncological treatment integrated with palliative care in the last month of life. The median duration of survival from diagnosis till death was 7 months in the patients who received only palliative care and 10 months in patients who received integrated onco-palliative care in the last month of life (P=0.452). 14 (51.8%) patients received early palliative care. The median survival of the patients who received early palliative care and of those who were offered palliative care towards the end of life was 8.5 months and 7 months respectively (P=0.040). Conclusion Based on our results, we strongly believe that early palliative care when integrated into standard oncological treatment in advance stage cancer patients can prolong patient's survival. PO-1253 Stereotactic Ablative Radiotherapy for spinal metastases: Experience at a Brazilian Institution G. Marta 1 , F. Miranda 1 , A. Silva 1 , S. Hanna 1 , W. Neves Jr 1 , F. De Arruda 1 , A. Mancini 1 , R. Gadia 1 , F. Moraes 2 1 Hospital Sírio-Libanês, Radiation Oncology, Sao Paulo, Brazil ; 2 Kingston Health Sciences Center- Queen's University, Radiation Oncology, Kingston, Canada Purpose or Objective In the last decade, stereotactic ablative radiotherapy (SABR) has arisen as an optimal treatment option for either oligometastatic and oligoprogressing patients with spine metastases. SABR allows the delivery of high-dose radiation to the specific target volume while sparing nearby organs at risk and increases the therapeutic

Results Forty-three patients died within 2 months (27%). Fifty- eight of the remaining 119 patients (48.7%) did report to have benefit of the treatment. Patients who were alive after 2 months and did benefit from treatment had a median survival of 8.1 months compared to 2.9 months for patients who reported no benefit. The median overall survival was 3.5 months (range 0.3-41.8). On univariate analysis of the whole patient population (Cox regression) the following parameters were significant: dose dexamethasone prior to WBRT (Hazard Ratio (HR): 0.628), Karnofsky score (HR: 1.509) and treatment options after WBRT (HR: 0.575). On multivariabele analysis both low dose dexamethasone (0-7 mg) (HR: 1.038) and the possibility of treatment options after WBRT (HR: 1.303) were significant. The existence of paraplegia prior to WBRT was nearly significant (p=0.064). Age, gender, time